Skip to main content
SpringerLink
Log in

Hochmaligne Non-Hodgkin-Lymphome

  • Chapter
Therapiekonzepte Onkologie

  • 69 Accesses

Zusammenfassung

Hochmaligne Non-Hodgkin-Lymphome (NHL) sind mit einem Anteil von ca. 2–3% an der Gesamtzahl seltene maligne Erkrankungen, deren jährliche Inzidenzrate aber stetig zunimmt und sich z.B. in den USA von 1950–1989 von 6,9 auf 13,7 pro 100000 Einwohner etwa verdoppelte. Die Ursachen dieser Entwicklung, die auch in Westeuropa zu beobachten ist, sind noch unbekannt [11, 106] und allein durch die seit Ende der achtziger Jahre entdeckten HIV-assoziierten NHL nicht zu erklären.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bastion Y, Blay JY, Divine M et al. (1997) Elderly patients with aggressive non-Hodgkin’s lymphoma: Disease presentation response to treatment, and survival — a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 15:2945–2953

    PubMed  CAS  Google Scholar 

  2. Brittinger G, Bartels H, Common H et al. (1984) Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas: results of a prospective multicenter study by the Kiel lymphoma study group. Hematol Oncol 2:269–306

    PubMed  CAS  Google Scholar 

  3. Cabanillas F, Hagemeister FB, Bodey GP et al. (1982) IMVP 16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693–697

    PubMed  CAS  Google Scholar 

  4. Camron DA, White JM, Proctor SJ et al. (1997) CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-hodgkins-lymphoma. European J Cancer 33:1195–1201

    Google Scholar 

  5. Coiffier B, Gisselbrecht C, Herbrecht R et al. (1989) LNH-94 regimen: a multi-center study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018–1026

    PubMed  CAS  Google Scholar 

  6. Chan WC, Armitage JO, Gascoyne R et al. (1997) A clinical evaluatio of the international lymphoma study group classification of non-Hodgkin’s-lymphoma. Blood 89:3909–3918

    Google Scholar 

  7. Coleman CN, Picozzi VJ, Cox RS et al. (1989) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:399–404

    Google Scholar 

  8. Connors JM, Klimo P, Fairy RN, Voss N (1987) Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Int Med 107:25–30

    PubMed  CAS  Google Scholar 

  9. Connors JM, Klimo P (1988) MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 25:41–46

    PubMed  CAS  Google Scholar 

  10. DeAngelis LM, Yahalom J, Thaler HAT et al. (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635–643

    PubMed  CAS  Google Scholar 

  11. Devesa SS, Fears T (1992) Non-Hodgkin-lymphoma time trends: United States and International Data. Cancer Res 52:5432–5440

    Google Scholar 

  12. DeVita VT Jr, Jaffe ES, Hellman S (1985) Hodgkin’s disease and the non-Hodgkin’s lymphomas. In: Cancer-principles and practice of oncology (eds DeVita VT, Hellman S, Rosenberg SA). JB Lippincott Company: 1623–1709

    Google Scholar 

  13. Dhaliwal HS, Rohatiner AZS, Gregory W et al. (1993) Combination chemotherapy for intermediate and high grade non-Hodgkin’s lymphoma. Br J Cancer 68: 767–774

    PubMed  CAS  Google Scholar 

  14. Dixon DO, Neilan B, Jones SE et al. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4:295–305

    PubMed  CAS  Google Scholar 

  15. Doglioni C, Wotherspoon AC, Moschini A et al. (1992) High incidence of primary gastric lymphoma in northeastern Italy. Lancet 339:834–835

    PubMed  CAS  Google Scholar 

  16. Donohue HJ, Habermann TM (1993) The management of gastric lymphoma. Surg Clin North Amer 2:231–232

    Google Scholar 

  17. Engelhard M, Brittinger G, Huhn D et al. (1997) Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 89:2291–2297

    Google Scholar 

  18. Engelhard M, Meusers P, Brittinger G et al. (1991) Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 2 (Suppl 2): 177–180

    PubMed  Google Scholar 

  19. Engert A, Schnell R, Küpper F et al. (1997) A phase-II study with idarubicin, ifos-famide, and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin’s lymphoma. Leukemia and Lymphoma 24:513–522

    PubMed  CAS  Google Scholar 

  20. Filipovich AH, Mathur A, Kamat D, Shapiro RS (1992) Primary immunodeficiencies: Genetic risk factors for lymphoma. Cancer Res 52 (Suppl): 5465–5467

    Google Scholar 

  21. Fischbach W, Kestel W, Kirchner T et al. (1992) Malignant lymphomas of the upper gastrointstinal tract: Results of a prospective study in 103 patients. Cancer 70:1075–1080

    PubMed  CAS  Google Scholar 

  22. Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    PubMed  CAS  Google Scholar 

  23. Fisher RI (1997) Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma. Cancer Chemother & Pharmacol 40:42–46

    Google Scholar 

  24. Gerhartz HH, Engelhard M, Brittinger G et al. (1993) Randomized, double-blind, placebo-controled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 82:2329–2339

    PubMed  CAS  Google Scholar 

  25. Gianni AM, Bregni M, Siena S et al. (1997) High dose chemotherapy and autologous Bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290–1287

    PubMed  CAS  Google Scholar 

  26. Gisselbrecht C, Bosly A, Lepage E et al. (1996) Short and intensified treatment with autologous stem cell transplantation (ASCT) versus ACVB regimen in poor prognosis aggressive lymphoma. Prognostic factors of induction failure. Ann Oncol 7 (Suppl. 3) 18 (Abstr. 056)

    Google Scholar 

  27. Gobbi PG, Diongi P, Barbieri F et al. (1990) The role of surgery in the multimodal treatment of primary gastric non-Hodgkin’s lymphomas. A report of 76 cases and review of the literature. Cancer 65:2528–2536

    PubMed  CAS  Google Scholar 

  28. Gordon LI, Harrington D, Andersen J et al. (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327:1342–1349

    PubMed  CAS  Google Scholar 

  29. Gordon LI, Andersen J, Habermann TM et al. (1996) Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM. J Col Oncol 14:1275–1281

    CAS  Google Scholar 

  30. Grogan L, Corbally N, Dervan PA et al. (1994) Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin’s lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol 5 (Suppl 1):47–51

    PubMed  Google Scholar 

  31. Haioun C, Lepage E, Gisselbrecht C et al. (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87–2. J Clin Oncol 12:2543–2551

    Google Scholar 

  32. Harris NL, Jaffe ES, Stein H et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    PubMed  CAS  Google Scholar 

  33. Hoelzer D, Thiel E, Löffler H et al. (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64:38–47

    PubMed  CAS  Google Scholar 

  34. Hoppe RT (1997) Hodgkin’s disease: Complications of therapy and excess mortality. Ann One 8:115–118

    Google Scholar 

  35. Jones SE, Müller TP, Connors JM (1989) Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7:1186–1191

    PubMed  CAS  Google Scholar 

  36. Juliusson G, Liliemark J (1996) Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (DCE) and filgrastim for poor-risk non-Hodgkin’s lymphoma. Ann Oncol 7:1037–1041

    PubMed  CAS  Google Scholar 

  37. Kadin ME (1994) Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 5 (Suppl 1): 25–30

    PubMed  Google Scholar 

  38. Kaminski MS, Zasadny KR, Francis IR et al. (1996) Iodine-131-anti-B1 radio-immunotherapy for B-cell lymphoma. J Clin Oncol 14:1974–1981

    PubMed  CAS  Google Scholar 

  39. Kath R, Höffken K, Günzel K et al. (1990) Chemotherapie des nicht-endemischen Burkitt-Lymphoms. Dtsch med Wschr 115:1219–1226

    PubMed  CAS  Google Scholar 

  40. Koch P, Grothaus-Pinke W, Hiddemann W et al. (1997) Primary lymphoma of the stomach: Three-year results of a prospective multicenter study. Ann Oncol 8 (Suppl 1):83–88

    Google Scholar 

  41. Köppler H, Pflüger KH, Eschenbach I et al. (1994) Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin’s lymphomas: Treatment results and prognostic risk factors analysis in a multi-centre trial. Ann Oncol 5:49–55

    PubMed  Google Scholar 

  42. Kwak L, Olshen R, Halpern J et al. (1988) Dose intensity: relationship to prognostic factors for diffuse large cell lymphoma. Proc Am Soc Clin Oncol 7:226 (abstr)

    Google Scholar 

  43. Lee KA, Finnegan MC, Sheridan E et al. (1994) Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin’s lymphomas. Annals of Oncology 5:85–88

    PubMed  Google Scholar 

  44. Lepage E, Gisselbrecht C, Haioun C et al. (1992) Relative received dose intensity (DI) in poor risk lymphoma patients: Higher DI correlates with longer survival. A study from GELA. Blood 80 (Suppl 1): 158 (abstr 621)

    Google Scholar 

  45. Lennert K, Feller AC (1990) Histopathologic der Non-Hodgkin-Lymphome. Springer Verlag

    Google Scholar 

  46. Liang R, Todd D, Chan TK et al. (1993) COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin’s lymphoma. Hematol Oncol 11:43–50

    PubMed  CAS  Google Scholar 

  47. Linch DC, Vaughan-Hudson B, Hancock BW et al. (1996) A randomized trial of a third generation regimen (PACEBOM) versus a standard regimen (CHOP) in histologically aggressive non-Hodgkin’s lymphoma: A BNLI report. Br J Cancer 74:318–322

    PubMed  CAS  Google Scholar 

  48. Longo DL, DeVita VT, Duffey PL et al. (1991) Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9:25–38

    PubMed  CAS  Google Scholar 

  49. Maksymiuk AW, Bratvold JS, Ezzat W et al. (1993) Non-Hodgkin’s-Lymphoma in Saskatchewan — a review of 10 years’ experience. Cancer 73:711–719

    Google Scholar 

  50. Magrath I (1992) Molecular basis of lymphomagenesis. Cancer Research 52 (Suppl): 5529–5540

    Google Scholar 

  51. Maor MH, Velasquez WS, Fuller LM, Silvermintz KB (1990) Stomach conservation in stages IE and HE gastric non-Hodgkin’s lymphoma. J Clin Oncol 8:266–271

    PubMed  CAS  Google Scholar 

  52. Martelli M, Vignetti M, Zinzani PL et al. (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: A prospective randomized italian multi-center study. J Clin Oncol 14:534–542

    PubMed  CAS  Google Scholar 

  53. McKelvey EM, Gottlieb JA, Wilson HE et al. (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493

    PubMed  CAS  Google Scholar 

  54. McMaster ML, Johnson DH, Greer JP et al. (1991) A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin’s lymphoma. Cancer 67:1487–1492

    PubMed  CAS  Google Scholar 

  55. Meerwaldt JH, Carde P, Somers RJ et al. (1997) Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/ Vm-26/prednisone combinatio (CHVmP-VB) in stage II–IV intermediate and high grade non-Hodgkin’s lymphoma. Ann Oncol 8 (Suppl 1):67–70

    PubMed  Google Scholar 

  56. Meyer RM, Hryniuk WM, Goodyear MGE (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 9:339–347

    PubMed  CAS  Google Scholar 

  57. Meyer RM, Quirt IC, Skillings JR et al. (1993) Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin’s lymphoma. N Engl J Med, 329:1770–1776

    PubMed  CAS  Google Scholar 

  58. Miller TP, Grogan TM, Dalton WS et al. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17–24

    PubMed  CAS  Google Scholar 

  59. Milpied N, Ifrah N, Kuentz M et al. (1989) Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remisson. Br J Haematol 73:82–87

    PubMed  CAS  Google Scholar 

  60. Montserrat E, Garcia-Conde J, Vinolas N et al. (1996) CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin’s lymphoma: Long term results of a multicenter randomized trial. Eur J Haematol 57:377–383

    PubMed  CAS  Google Scholar 

  61. Morel P, Lepage E, Brice P et al. (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report of 80 patients. J Clin Oncol 10(7): 1078–1085

    PubMed  CAS  Google Scholar 

  62. Niehans GA, Jaszcz W, Brunetto V et al. (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768–3775

    PubMed  CAS  Google Scholar 

  63. Nissen NI, Ersbøll J, Hansen HS et al. (1983) A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I–II non-Hodgkin’s lymphomas. Cancer 52:1–7

    PubMed  CAS  Google Scholar 

  64. Nouwrousian MR, Mengelkoch B, Kleine-Herzbruch R et al. (1993) Intensified sequential combination chemotherapy (CEBOPP/VIML), G-CSF and radiation in patients with high grade malignant non-Hodgkin’s lymphoma (NHL). Ann Hematol 67 (Suppl): A88

    Google Scholar 

  65. O’Brien JP, O’Keefe P, Alvarez A et al. (1995) The NHL-15-protocol for diffuse aggressive lymphomas: Two year median follow-up of the first 100 patients. Proc of Amer Soc Clin Oncol 14:393 Abstract

    Google Scholar 

  66. O’Connel MJ, Anderson J, Earle JD et al. (1984) Combined modality therapy of advanced unfavorable non-Hodgkin’s lymphoma (NHL). An ECOG randomized clinical trial. Proc Amer Soc Onc 241

    Google Scholar 

  67. Offït K, Lo Coco F, Louie DC et al. (1994) Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331:74–80

    PubMed  Google Scholar 

  68. O’Reilly S, Klimo P, Connors JM et al. (1991) Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9:741–747

    PubMed  Google Scholar 

  69. Ostermann B, Jonsson H, Tavelin B, Lenner P (1993) Non-Hodgkin’s lymphoma in northern Sweden. Acta Oncologica 32:507–515

    Google Scholar 

  70. Parsonnet JS, Hansen L, Rodriguez L et al. (1994) Heliobacter pylori infection and gastric lymphoma. N Engl J Med 330:1267–1271

    PubMed  CAS  Google Scholar 

  71. Pettengel R, Crowther C (1994) Hemopoetic growth factors and dose intensity in high-grade and intermediate-grade non-Hodgkin’s lymphoma. Ann Oncol 5:133–141

    Google Scholar 

  72. Pittaluga S, Bijnens L, Teodorovic I et al. (1996) Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma cooperative Group subtyped according to the Revised European-American Classification of lymphoid neoplasms: A comparison with the Working Formulation

    Google Scholar 

  73. Philip T, Guglielmi C, Somers R et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med 333:1540–1545

    PubMed  CAS  Google Scholar 

  74. Sack H, Budach V, Stuschke M, Hoederat A (1992) Non-Hodgkin lymphomas (NHL) — Early stages: Interim results of a multi-centre trial. Cancer Res Clin Oncol 118 (Suppl): R115

    Google Scholar 

  75. Salles G, Shipp MA, Coiffier B (1994) Chemotherapy of non-Hodgkin’s aggressive lymphomas. Semin Hematol 31:46–69

    PubMed  CAS  Google Scholar 

  76. Santini G, Congui AM, Coser P et al. (1991) Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first CR: A study of the NHLGSG. Leukemia 5 (Suppl 1): 42–45

    PubMed  Google Scholar 

  77. Scherr PA, Hutchinson GB, Neiman RS (1992) Non-Hodgkin’s lymphoma and occupational exposure. Cancer Res 52 (Suppl): 5503–5509

    Google Scholar 

  78. Schultz C, Scott C, Sherman W et al. (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy oncology group protoco 88–06.1 Clin Oncol 14:556–564

    CAS  Google Scholar 

  79. Shapiro RS, McClain K, Frizzera G et al. (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234–1243

    PubMed  CAS  Google Scholar 

  80. Shipp MA (1997) Can we improve upon the International Index? Ann Oncol 8(Suppl 1):43–47

    PubMed  Google Scholar 

  81. Shipp MA, Neuberg D, Janicek M et al. (1995) High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin’s lymphoma: A dose-finding pilot study. J Clin Oncol 13:2916–2920

    PubMed  CAS  Google Scholar 

  82. Shipp MA, Yeap BY, Harrington DP et al. (1990) The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8: 84–93

    PubMed  CAS  Google Scholar 

  83. Siebert R, Zhang Y, Matthiesen P et al. (1997) Molekularzytogenetische Untersuchungen bei malignen Lymphomen: Neue Erkenntnisse für Biologie, Klassifikation und Klinik durch FISH, FICTION und CHG. In: Höffkes HG und Uppenkamp M (Hrsg): Maligne Lymphome. Biologie, Klassifikation und Klinik, Springer Verlag, Berlin, Heidelberg, 73–88

    Google Scholar 

  84. Slater DE, Mertelsmann R, Kaziner B et al. (1986) Lymphoblastic lymphoma in adults. J Clin Oncol 4:57–67

    PubMed  CAS  Google Scholar 

  85. Solal-Celigny P, Chastang C, Herrera A et al. (1987) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 6:1838–1844

    Google Scholar 

  86. Somers R, Carde P, Thomas J et al. (1994) EORTC study of non-Hodgkin’s lymphoma: Phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate and high grade lymphoma. Ann Oncol 5 (Suppl 2): 85–89

    PubMed  Google Scholar 

  87. Sonneveld P, Michiels JJ (1990) Full dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer 62:105–108

    PubMed  CAS  Google Scholar 

  88. Stansfield AG, Diebold J, Kapanci Y et al. (1988) Updated Kiel classification for lymphomas. The Lancet: 292–293

    Google Scholar 

  89. Steinke B, Buss K, Reinold H-M (1992) Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin’s lymphomas with VIM-Bleo and CHOP. Eur J Cancer 28:100–104

    PubMed  CAS  Google Scholar 

  90. Stoppa AM, Bouabdallah R, Chabannon C et al. (1997) Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-hodgkin’s-lymphoma. J Clin Oncol 15:1722–1729

    PubMed  CAS  Google Scholar 

  91. Taal BG, den Hartog-Jager FCA, Burgers JMV et al. (1989) Primary non-Hodgkin’s lymphoma of the stomach: changing aspects and therapeutic choices. Eur J Cancer Clin Oncol 25:439–450

    PubMed  CAS  Google Scholar 

  92. Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda H (1994) Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulationg factor in non-Hodgkin’s lymphoma. Cancer 74:1939–1944

    PubMed  CAS  Google Scholar 

  93. The International Non-Hodgkin’s lymphoma prognostic factors project (1993) A predictive model for aggressive Non-Hodgkin’s-lymphoma. N Engl J Med 329:987–949

    Google Scholar 

  94. The Non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute sponsored study of classifications of Non-Hodgkin’s lymphomas. Summary and description of a working Formulation for clinical usage. Cancer 9:2112–2121

    Google Scholar 

  95. Tigaud J-D, Demolombe S, Bastion Y et al. (1991) Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematol Oncol 9:225–233

    PubMed  CAS  Google Scholar 

  96. Tirelli U, Zagonel V, Errante D et al. (1992) A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin’s lymphoma. J Clin Oncol 10:228–236

    PubMed  CAS  Google Scholar 

  97. Tondini C, Zanini M, Lombardi F et al. (1993) Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I and II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol 11:720–725

    PubMed  CAS  Google Scholar 

  98. Tondeshini G, Tecchio C, Degani D et al. (1997) Eighty-one percent event-free survival in advanced Burkitt’s lymphoma/leukemia: No difference in outcome between adult and pediatric patients treated with the same intensive pediatirc protocol. Ann Oncol 8:77–81

    Google Scholar 

  99. Trümper L, Renner Ch, Nahler M et al. (1994) Intensification of the CHOEP regimen for high grade non-Hodgkin’s lymphoma by G-CSF: Feasibility of a 14-day regimen. Onkologie 17:69–71

    Google Scholar 

  100. Velasquez WS, Cabanillas F, Salvadore P et al. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexa-methasone (DHAP). Blood 71:117–122

    PubMed  CAS  Google Scholar 

  101. Velasquez WS, Hagemeister F, McLaughlin P et al. (1994) E-SHAP — An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow up study. J Clin Oncol 12:1169–1176

    PubMed  CAS  Google Scholar 

  102. Verdonck LF, Van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, Van Imhoff GW, Kluinemans HC, Raemaekers JMM, Van Oers RHJ, Haak HL, Schots R, Dekker AW, De Gast GC, Löwenberg B (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 332:1045–1051

    PubMed  CAS  Google Scholar 

  103. Vose JM, Armitage JO, Weisenburger DD et al. (1988) The importance of age in survival of patients treated with chemotherapy for agressive non-Hodgkin’s lymphoma. J Clin Oncol 6:1838–1844

    PubMed  CAS  Google Scholar 

  104. Waits TM, Greco FA, Greer JP et al. (1993) Effective therapy for poor-prognosis non-Hodgkin’s lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. J Clin Oncol 11:943–949

    PubMed  CAS  Google Scholar 

  105. Weick JK, Dahlberg S, Fisher RIO et al. (1991) Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin’s lymphoma with MACOP-B: a southwest oncology group study. J Clin Oncol 9:748–753

    PubMed  CAS  Google Scholar 

  106. Weisenburger DD (1994) Epidemiology of non-Hodgkin’s lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 5 (Suppl 1):19–24

    PubMed  Google Scholar 

  107. Welt A, Anhuf J, Fossa A et al. (1997) High dose sequential combination chemotherapy in the initial treatment of aggressive non-Hodgkin’s lymphomas with risk factors. Onkilogie 20 (Suppl 1): 115 (Abstr.)

    Google Scholar 

  108. Wilson WH, Bryant G, Bates S et al. (1993) EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol 11: 1573–1582

    PubMed  CAS  Google Scholar 

  109. Wilson WH, Bates SE, Fojo A et al. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Onc 13:1995–2004

    CAS  Google Scholar 

  110. Winkler U, Barth S, Schnell R et al. (1997) The emerging role of immunotoxins in leukemia and lymphoma. Ann Onc 8 (Suppl 1):139–146

    Google Scholar 

  111. Wolf M, Matthews JP, Stone J et al. (1997) Long-term survival advantage of MACOP-B over CHOP in intermediate non-Hodgkin’s lymphomas. Ann Onc 8 (Suppl 1):71–75

    Google Scholar 

  112. Yunis JJ, Mayer MG, Arnesen MA et al. (1989) Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320:1047–1054

    PubMed  CAS  Google Scholar 

  113. Zahm SH, Blair A (1992) Pesticides and Non-Hodgkin’s lymphoma. Cancer Res 52 (Suppl): 5485–5488

    Google Scholar 

  114. Ziegler JL (1981) Burkitt’s lymphoma. N Engl J Med 305:735–745

    PubMed  CAS  Google Scholar 

  115. Zinzani PL, Bendani M, Martelli M et al. (1996) Anaplastic large cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955–962

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Engelhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Trenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Brittinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Engelhard, M., Trenn, G., Brittinger, G. (1998). Hochmaligne Non-Hodgkin-Lymphome. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation